Tower Research Capital (TRC)’s Cellebrite CLBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$279K Buy
+24,816
New +$330K ﹤0.01% 2134
2026
Q2
– Sell
-1
Closed -$14 – 5260
2026
Q1
$14 Buy
+1
New +$15 ﹤0.01% 5068
2025
Q4
– Sell
-1,179
Closed -$21.8K – 5202
2025
Q3
$21.8K Sell
1,179
-1,059
-47% -$16.6K ﹤0.01% 3237
2025
Q2
$35.8K Buy
+2,238
New +$39.9K ﹤0.01% 3258
2025
Q1
– Sell
-76
Closed -$1.67K – 5266
2024
Q4
$1.67K Sell
76
-3,405
-98% -$65.5K ﹤0.01% 4984
2024
Q3
$58.6K Sell
3,481
-31,536
-90% -$468K ﹤0.01% 2636
2024
Q2
$418K Buy
35,017
+29,914
+586% +$334K 0.01% 1484
2024
Q1
$56.5K Buy
+5,103
New +$52.1K ﹤0.01% 2189
2022
Q2
– Sell
-596
Closed -$4K – 6112
2022
Q1
$4K Buy
+596
New +$3.95K ﹤0.01% 5186
2021
Q4
– Sell
-1,363
Closed -$13K – 6170
2021
Q3
$13K Buy
+1,363
New +$14.2K ﹤0.01% 4068

Other funds holding CLBT

Tower Research Capital (TRC)'s CLBT Position: Q3 2026 in Review

Tower Research Capital (TRC) opened a new position in Cellebrite (CLBT) in Q3 2026: 24,816 shares worth $279K. The stake represents ﹤0.01% of the portfolio and ranks #2134 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CLBT as recently as Q1 2026.

Tower Research Capital (TRC) first reported a position in CLBT in Q3 2021 and has held it in 10 quarters since. The position peaked at $418K in Q2 2024. 197 funds tracked by Wall St. Rank hold CLBT as of Q3 2026.

  • Tower Research Capital (TRC) held 24,816 shares of Cellebrite worth $279K as of Q3 2026.
  • Cellebrite was a new Tower Research Capital (TRC) position in Q3 2026.
  • Cellebrite made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #2134 holding.
  • Tower Research Capital (TRC) first reported a position in Cellebrite in Q3 2021 and has held it in 10 quarters since.
  • Tower Research Capital (TRC)'s Cellebrite position peaked at $418K in Q2 2024.
  • 197 funds tracked by Wall St. Rank held Cellebrite as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.